Year-end Sale % OFF 
Abstract
PHERIC-1 is an italian multicenter, double-blind, placebo-controlled trial aimed to investigate the safety and the hemodynamic effects of sustained sildenafil (Sld) administration in COPD-associate out-of-proportion pulmonary hypertension (COPD-OoPPH) (http://clinicaltrials.gov/ct2/show/NCT01441934). Primary end-points: reduction in pulmonary vascular resistance (PVR), and drop in PaO2. ITT analysis of the results is presented.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
